JP7110199B2 - 抗第ＸＩ／ＸＩａ因子抗体による処置法 - Google Patents

抗第ＸＩ／ＸＩａ因子抗体による処置法 Download PDF

Info

Publication number
JP7110199B2
JP7110199B2 JP2019533396A JP2019533396A JP7110199B2 JP 7110199 B2 JP7110199 B2 JP 7110199B2 JP 2019533396 A JP2019533396 A JP 2019533396A JP 2019533396 A JP2019533396 A JP 2019533396A JP 7110199 B2 JP7110199 B2 JP 7110199B2
Authority
JP
Japan
Prior art keywords
antibody
fxi
seq
amino acid
fxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504110A5 (enExample
JP2020504110A (ja
Inventor
フリードマン，カローラ
キーダー，ヤセル
レフコウィッツ，マーティン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020504110A publication Critical patent/JP2020504110A/ja
Publication of JP2020504110A5 publication Critical patent/JP2020504110A5/ja
Priority to JP2022115212A priority Critical patent/JP7500662B2/ja
Application granted granted Critical
Publication of JP7110199B2 publication Critical patent/JP7110199B2/ja
Priority to JP2024091065A priority patent/JP7864156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019533396A 2016-12-23 2017-12-22 抗第ＸＩ／ＸＩａ因子抗体による処置法 Active JP7110199B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022115212A JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2024091065A JP7864156B2 (ja) 2016-12-23 2024-06-05 抗第ＸＩ／ＸＩａ因子抗体による処置法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US62/438,654 2016-12-23
US201762589851P 2017-11-22 2017-11-22
US62/589,851 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022115212A Division JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法

Publications (3)

Publication Number Publication Date
JP2020504110A JP2020504110A (ja) 2020-02-06
JP2020504110A5 JP2020504110A5 (enExample) 2021-04-30
JP7110199B2 true JP7110199B2 (ja) 2022-08-01

Family

ID=61022382

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533396A Active JP7110199B2 (ja) 2016-12-23 2017-12-22 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2022115212A Active JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022115212A Active JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法

Country Status (9)

Country Link
US (3) US20200231701A1 (enExample)
EP (1) EP3558370A2 (enExample)
JP (2) JP7110199B2 (enExample)
KR (3) KR102918597B1 (enExample)
CN (2) CN118320078A (enExample)
AU (2) AU2017383537B2 (enExample)
CA (1) CA3048157A1 (enExample)
IL (2) IL267519B2 (enExample)
WO (1) WO2018116267A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963166C (en) 2014-10-01 2023-10-03 Medimmune Limited Antibodies to ticagrelor and methods of use
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
FI3852617T3 (fi) * 2018-09-20 2025-10-21 Sfj Pharma X Inc Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
WO2020211674A1 (zh) * 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN115003325A (zh) * 2019-12-20 2022-09-02 安托斯治疗股份有限公司 因子xi/xia抗体的药物制剂和剂量方案
KR20230034361A (ko) * 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
WO2025201156A1 (zh) * 2024-03-28 2025-10-02 施能康生物医药（苏州）有限公司 靶向凝血因子xi的核酸及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517305A (ja) 2012-05-10 2015-06-22 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
JP2018526976A (ja) 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE69901569T2 (de) * 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
LT2373691T (lt) * 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517305A (ja) 2012-05-10 2015-06-22 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
JP2018526976A (ja) 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Also Published As

Publication number Publication date
IL267519B1 (en) 2024-12-01
JP2022141831A (ja) 2022-09-29
JP7500662B2 (ja) 2024-06-17
CN110325211A (zh) 2019-10-11
KR20260023597A (ko) 2026-02-20
KR102702288B1 (ko) 2024-09-05
CA3048157A1 (en) 2018-06-28
KR20240134248A (ko) 2024-09-06
JP2024116221A (ja) 2024-08-27
WO2018116267A3 (en) 2018-08-02
IL267519B2 (en) 2025-04-01
US20230002507A1 (en) 2023-01-05
US20250197522A1 (en) 2025-06-19
CN118320078A (zh) 2024-07-12
KR102918597B1 (ko) 2026-01-28
EP3558370A2 (en) 2019-10-30
AU2024287181A1 (en) 2025-03-06
IL316673A (en) 2024-12-01
IL267519A (en) 2019-08-29
KR20190099256A (ko) 2019-08-26
WO2018116267A2 (en) 2018-06-28
US20200231701A1 (en) 2020-07-23
AU2017383537B2 (en) 2024-10-03
AU2017383537A1 (en) 2019-06-27
JP2020504110A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
JP7823009B2 (ja) 第ｘｉ因子抗体および使用方法
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP7139332B2 (ja) 第ｘｉ因子抗体および使用方法
JP7864156B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250